The chart below shows how EVGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EVGN sees a +5.42% change in stock price 10 days leading up to the earnings, and a -6.15% change 10 days following the report. On the earnings day itself, the stock moves by -3.54%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Earnings Surprise: Evogene Ltd. reported an EPS of $0.06, significantly beating expectations of $-0.72.
Revenue Increase 2024: Total revenues for 2024 reached approximately $8.5 million, up from $5.6 million in 2023, indicating strong growth.
Revenue Increase Overview: In Q4 2024, total revenues were approximately $1.6 million, compared to $0.6 million in Q4 2023, showcasing a substantial increase.
Seed Sales Revenue Growth: Casterra's seed sales contributed to revenue growth, with 250 tons of castor seeds delivered in February 2025 alone, indicating a recovery in production capacity.
AI Drug Discovery Collaboration: Evogene established a collaboration with Google Cloud to develop a GenaRator AI foundation model for drug discovery, reflecting innovation in technology.
R&D Expense Reduction: R&D expenses decreased to approximately $16.6 million in 2024 from $20.8 million in 2023, indicating improved cost management.
Expense Reduction Strategy: The company implemented an expense reduction plan expected to lower costs by approximately 30% starting Q1 2025.
Therapeutic Development Progress: Biomica's clinical study for BMC128 is nearing completion with positive responses from patients, indicating progress in therapeutic development.
Collaboration for Sustainable Weed Control: AgPlenus signed a new collaboration agreement with Bayer for sustainable weed control, enhancing its market position.
Castor Seed Shipment Milestone: Casterra achieved a key milestone with the first shipment of over 100 tons of castor seeds grown in Kenya, expanding its operational footprint.
Negative
Modest Revenue Growth: Total revenues for 2024 were approximately $8.5 million, which, while an increase from $5.6 million in 2023, still reflects a modest growth that may not meet investor expectations for a company in a high-growth sector.
Revenue Shortfall Analysis: In Q4 2024, total revenues were approximately $1.6 million, significantly lower than expected due to a change in the delivery schedule of Casterra’s seeds, which indicates operational inefficiencies.
Production Bottleneck Analysis: Casterra delivered only 76 tons of castor seeds in Q4 2024, while it had already delivered 250 tons in February 2025 alone, highlighting a significant backlog and production bottleneck in the previous quarter.
R&D Expense Decline: R&D expenses for 2024 were approximately $16.6 million, down from $20.8 million in 2023, but this decrease was largely due to the cessation of Canonic’s activities, raising concerns about the sustainability of R&D investment in the future.
Rising Operational Costs: General and administrative expenses increased to approximately $7.4 million in 2024 from $6.1 million in 2023, indicating rising operational costs that could impact profitability.
Operating Loss Reduction: The operating loss for 2024 was approximately $22.2 million, a decrease from $26.5 million in the previous year, but still reflects a significant financial burden on the company.
Net Loss Comparison: The net loss for 2024 was approximately $18.1 million, compared to $26 million in 2023, which, while improved, still raises concerns about the company's long-term financial health and ability to achieve profitability.
Evogene Ltd. (NASDAQ:EVGN) Q4 2024 Earnings Call Transcript
EVGN.O
3.62%